ACTRN12620001150932
Not yet recruiting
未知
Cytokine (proinflammatory/anti-inflammatory) analysis in Myalgic Encephalomyelitis Chronic Fatigue Syndrome (MECFS) patients: A Two Phase Design. Assessing differences in cytokine levels across two time points.
South Australian Health & Medical Research Institute0 sites60 target enrollmentNovember 3, 2020
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- South Australian Health & Medical Research Institute
- Enrollment
- 60
- Status
- Not yet recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants will have a diagnosis of ME/CFS. They will be based in South Australia unless special arrangements can be organised to collect bloods interstate. A formal diagnosis of ME/CFS will have been made by a general practitioner or medical specialist. They will also consent for their GP to be provided with information if required for example feedback about clinical levels of moderate to severe depression. Healthy participants will be those who do not have other current physical health or mental health problems. They will also consent for their GP to be provided with information if required for example feedback about clinical levels of moderate to severe depression.
Exclusion Criteria
- •Exclusion criterion includes hormonal disorders, major physical or mental health disorders, or outside of the age range. Exclusion criteria include pregnancy, other diseases requiring medication that may affect the results, alcohol or substance abuse or dependence. Other physical disorders that may confound the measurements listed earlier, such as anaemia, or a thyroid disorder. Any mental health disorder that requires medication, psychosis, affective disorders. Low dosages of antidepressant for the purpose of sleep will be accepted. Being unable to understand the consent process due to language or an inability to read English. Must be at least 18 years of age, and up to 65 years.
- •Morbid Obesity will be an exclusion factor i.e. must have a BMI \<40 (35 equates to the WHO obesity type ii and 40 morbidly obese).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The mass of inflammatory cytokines are related to colon or rectum pre/post operation. Study of cytokine and postoperative complication.Colon cancer, colon/rectum perforationJPRN-UMIN000009793Juntendo University, faculty of medicine70
Not yet recruiting
Phase 3
Beneficial effects of ACE II inhibitor and ARB on inflammation and lung function in COPD and hypertension patients.Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecifiedHealth Condition 2: I10- Essential (primary) hypertensionCTRI/2024/08/072079Defense Research and Development Organization Life Science Research Board
Active, not recruiting
Not Applicable
Evaluation of the expression of inflammatory cytokines in the gingival crevicular fluid of patients with Covid-19.inflammationC01.748.214RBR-4473k7yniversidade Estadual do Oeste do Paraná
Active, not recruiting
Phase 1
Cytokines and inflammatory proteins gene expression study in synovial biopsies from rheumatoid arthritis patients refractory to anti-TNF therapy treated with Rituximab - Anti TNF resistant RA / RTX / miniRheumatoid arthritis refractory to TNF blockers patientsMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-005386-19-BECliniques Universitaires Saint-Luc20
Active, not recruiting
Not Applicable
ntersuchung der antiinflammatorischen Eigenschaften von Clopidogrel im Vergleich zu Acetylsalicylsäure bei Patienten mit chronischer ischämischer KardiomyopathieDas Ziel dieser Untersuchung ist es, zu evaluieren, ob und welche antiinflammatorischen Effekte Clopidogrel 75 mg im Vergleich zu Acetylalicylsäure (ASS) 100 mg bei Patienten mit chronischer ischämischer Kardiomyopathie aufweist. Untersucht werden soll dieses mittels Evaluation der peripheren endothelialen Stickstoffmonoxid-(NO) Bioverfügbarkeit sowie durch Bestimmung der Spiegel zirkulierender Peroxidasen wie Myeloperoxidase (MPO) oder Xanthin Oxidase (XO).EUCTR2006-000001-27-DEniversitäres Herzzentrum, Klinik für Kardiologie und Angiologie